deltatrials

Overactive bladder Trials in Los Angeles, United States

Conditions / Overactive bladder / Los Angeles, United States

Overactive bladder is a medical condition with active clinical research programs worldwide.

19 total trials for this combination

Showing top 10 of 19 trials

Trials

NCT ID Title Status Phase
NCT03902080 Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) COMPLETED PHASE3
NCT01868516 Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder COMPLETED PHASE2
NCT02045862 A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder COMPLETED PHASE3
NCT02660138 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 TERMINATED PHASE3
NCT01972841 This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder COMPLETED PHASE3
NCT03492281 A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) COMPLETED PHASE3
NCT02757768 A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) COMPLETED PHASE4
NCT00685113 A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder COMPLETED PHASE3
NCT03475706 Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women COMPLETED PHASE2
NCT03583372 An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). COMPLETED PHASE3

Related Pages